Showing results (191-200 of 201) with videos related to
Sort By:
Pageof 21
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 11, 2009
Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034Martin J van den Bent, Alba A Brandes, Roy Rampling, et al.The Oncologist|September 30, 2018
A Randomized Phase II Trial (TAMIGA) Evaluating the Efficacy and Safety of Continuous Bevacizumab Through Multiple Lines of Treatment for Recurrent GlioblastomaAlba A Brandes, Miguel Gil-Gil, Frank Saran, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 20, 2006
Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trialMartin J van den Bent, Antoine F Carpentier, Alba A Brandes, et al.International Journal of Molecular Sciences|May 9, 2017
Biomarker and Histopathology Evaluation of Patients with Recurrent Glioblastoma Treated with Galunisertib, Lomustine, or the Combination of Galunisertib and LomustineDavid Capper, Andreas von Deimling, Alba A Brandes, et al.Cancers|November 26, 2022
Characteristics, Patterns of Care and Predictive Geriatric Factors in Elderly Patients Treated for High-Grade <i>IDH</i>-Mutant Gliomas: A French POLA Network StudyColine Montégut, Jean-Sébastien Guillamo, François Ducray, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 22, 2021
First-In-Human Phase I Study of a Next-Generation, Oral, TGFβ Receptor 1 Inhibitor, LY3200882, in Patients with Advanced CancerTimothy A Yap, Maria Vieito, Capucine Baldini, et al.Journal of Neurology|January 2, 2021
SARS-CoV-2 infection in patients with primary central nervous system lymphomaAlice Laurenge, Renata Ursu, Caroline Houillier, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 18, 2021
Eprenetapopt Plus Azacitidine in <i>TP53</i>-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myélodysplasies (GFM)Thomas Cluzeau, Marie Sebert, Ramy Rahmé, et al.Neuro-Oncology|April 14, 2022
Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trialAntonio Omuro, Alba A Brandes, Antoine F Carpentier, et al.Neurology|September 20, 2015
Allelic loss of 9p21.3 is a prognostic factor in 1p/19q codeleted anaplastic gliomasAgustí Alentorn, Caroline Dehais, François Ducray, et al.Pageof 21